血脑屏障芯片：神经血管界面建模

以下为英文全文（English full text）

1. Introduction: The Neurovascular Challenge in CNS Drug Development

The blood-brain barrier (BBB) is the most restrictive vascular barrier in the human body, protecting the central nervous system (CNS) from circulating toxins, pathogens, and blood-borne immune cells while regulating the transport of nutrients and waste products. Composed of brain microvascular endothelial cells (BMECs) interconnected by tight junctions, surrounded by pericytes, astrocytes, and neurons, the BBB maintains an extremely low permeability to most small molecules and virtually excludes macromolecules [1].

This protective function poses a formidable challenge for CNS drug development: over 98% of small-molecule drugs and nearly 100% of biologics fail to cross the BBB in therapeutically relevant amounts. Consequently, neurodegenerative diseases including Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis (ALS) lack effective disease-modifying therapies. Traditional in vitro BBB models—transwell cultures of BMECs—exhibit leakier barriers than in vivo, while animal BBB models differ substantially from human in terms of transporter expression, tight junction composition, and receptor profiles [2].

BBB-on-chip (BBB-oC) technology addresses these limitations by recreating the neurovascular unit within microfluidic devices, incorporating shear stress, cell-cell interactions, and 3D architecture to achieve physiologically relevant barrier properties. These platforms are transforming CNS drug screening, neurotoxicity assessment, and disease modeling [3].

2. BBB Anatomy and Physiological Parameters

The neurovascular unit comprises multiple cell types that collectively regulate BBB function:

Brain Microvascular Endothelial Cells (BMECs)

• Express tight junction proteins (claudin-5, occludin, ZO-1, ZO-2)
• Low transcytosis rate (receptor-mediated and adsorptive)
• Express specialized transporters (GLUT1, LAT1, transferrin receptor, insulin receptor)
• High electrical resistance: 1500–8000 Ω·cm² (in vivo)
• Low permeability: Pe (sucrose) < 1×10⁻⁷ cm/s

Pericytes

• Coverage of capillary surface: 20–30%
• Regulate endothelial tight junction expression and angiogenesis
• Express PDGFR-β and NG2

Astrocytes

• End-feet processes envelop 99% of capillary surface
• Secrete laminin, sonic hedgehog, and angiopoietin-1 to induce BBB properties
• Maintain potassium homeostasis and neurotransmitter recycling

Neurons

• Modulate local blood flow and BBB permeability through neurovascular coupling
• Release VEGF, glutamate, and other vasoactive substances

Physiological Hemodynamics

• Cerebral blood flow velocity: 100–500 μm/s in capillaries
• Wall shear stress: 5–20 dyn/cm² (higher than peripheral vessels)
• Brain interstitial fluid pressure: -2 to +2 mmHg

3. BBB-on-Chip Design and Microfluidic Architectures

3.1 Planar Bilayer Membrane Devices

The most common BBB-oC design employs two parallel microchannels separated by a porous membrane, analogous to the lung-on-chip and kidney-on-chip configurations. BMECs are seeded on the upper (luminal/blood) channel, while astrocytes and/or pericytes are cultured on the lower (abluminal/brain) channel. The membrane (typically polyester or PDMS, 0.4–3.0 μm pores) enables molecular exchange while maintaining cellular compartmentalization [4].

Key parameters:

• Channel width: 500–2000 μm
• Channel height: 100–200 μm
• Membrane pore size: 0.4–1.0 μm (for tight barrier) or 3.0–5.0 μm (for immune cell transmigration)
• Flow rate: 10–100 μL/min (generating 5–20 dyn/cm² shear stress)
• Culture duration: 3–7 days for barrier maturation

3.2 3D Self-Assembly Models

Advanced BBB-oC platforms use hydrogel barriers (fibrin, collagen, Matrigel) to recreate the basement membrane in three dimensions. BMECs, pericytes, and astrocytes self-organize around the hydrogel, forming a cylindrical vessel-like structure. Straehla et al. (2022) developed a vascularized glioblastoma model with self-assembled ECs, astrocytes, and pericytes in coculture, demonstrating BBB transport properties comparable to in vivo mouse brain [5].

3.3 Micropatterned Transwell Models

Singh et al. developed a hybrid BBB model integrating micropatterned ECM proteins on porous transwells with perfusion systems. Linear or ring geometries of ECM proteins (fibronectin, collagen) guide endothelial cell alignment, replicating the longitudinal and radial cross-sections of blood vessels. This approach enables investigation of micromechanical forces on tight junction expression and barrier properties [6].

3.4 Membrane-Free Vertical Designs

Emulate's Chip-A1 (launched 2023) is a membrane-free BBB model that offers advanced imaging capabilities for testing neuroinflammatory treatments. This design eliminates the artificial membrane barrier, allowing direct cell-cell contact and improved optical access for high-resolution microscopy [7].

4. Cell Culture and Co-Culture Protocols

Primary Human BMECs

Primary BMECs isolated from human brain tissue provide the most physiologically relevant barrier properties but are scarce and exhibit donor variability. Cells are seeded at 2–5×10⁵ cells/cm² on collagen IV (100 μg/mL) and fibronectin (50 μg/mL) coated surfaces. Culture medium typically includes endothelial basal medium (EBM-2) with hydrocortisone (1.4 μM), cAMP (250 μM), and RO-20-1724 (17.5 μM) to enhance tight junction formation [4].

iPSC-Derived BMECs

iPSC-derived BMECs have emerged as a renewable, scalable alternative to primary cells. Differentiation protocols (typically 8–12 days) recapitulate developmental signaling (Wnt/β-catenin, retinoic acid) to generate BMECs expressing claudin-5, occludin, GLUT1, and P-glycoprotein. iPSC-BMECs achieve TEER values of 2000–5000 Ω·cm² when cultured on-chip with astrocytes, approaching in vivo values [8].

Co-Culture Configurations

• BMEC + Astrocytes: Astrocyte-conditioned medium or direct co-culture via membrane pores induces claudin-5 and occludin expression. Astrocyte end-feet processes can extend through 3.0 μm pores to contact endothelial cells.
• BMEC + Pericytes: Pericytes secrete TGF-β and angiopoietin-1, stabilizing vessels and reducing transcytosis.
• Tri-culture (BMEC + Pericytes + Astrocytes): The complete neurovascular unit achieves the highest TEER values and lowest permeability, most closely matching in vivo BBB properties [1].
• Neuronal Integration: Inclusion of iPSC-derived neurons or organoids enables study of neurovascular coupling, neuroinflammation, and neurotoxicity in the context of neuronal activity.

5. Functional Validation and Barrier Characterization

Trans-Endothelial Electrical Resistance (TEER)

TEER is the primary metric for BBB integrity. In vivo BBB TEER ranges from 1500–8000 Ω·cm². Transwell models typically achieve 200–400 Ω·cm², while BBB-on-chip platforms with tri-culture and shear stress reach 1000–5000 Ω·cm², representing a major improvement in physiological relevance [4].

Permeability Assays

• Paracellular permeability: Sodium fluorescein (376 Da), FITC-sucrose (342 Da), [¹⁴C]-sucrose
• Transcellular permeability: Propranolol (lipophilic), caffeine, antipyrine
• Efflux transporter activity: Rhodamine-123 (P-gp substrate), Hoechst 33342 (BCRP substrate), fluorescein-methotrexate (MRP substrate)
• Receptor-mediated transport: Transferrin-Alexa Fluor 488 (transferrin receptor), insulin-FITC (insulin receptor)

Immunocytochemistry

• Tight junctions: Claudin-5, occludin, ZO-1, ZO-2, tricellulin
• Adherens junctions: VE-cadherin, β-catenin
• Transporters: P-glycoprotein (ABCB1), BCRP (ABCG2), MRPs (ABCC family), GLUT1 (SLC2A1)
• Basement membrane: Collagen IV, laminin, fibronectin, nidogen
• Cell-specific markers: CD31 (endothelial), NG2/pericytes (pericytes), GFAP/S100β (astrocytes), MAP2/β-III tubulin (neurons)

Transcriptomic and Proteomic Analysis

RNA sequencing, mass spectrometry-based proteomics, and single-cell RNA-seq provide comprehensive characterization of BBB-oC molecular profiles. Benchmarking studies compare in vitro expression with in vivo human brain transcriptomic datasets to validate model fidelity [9].

6. CNS Drug Screening and Neurotoxicity Applications

Permeability Screening

BBB-on-chip platforms enable high-throughput screening of compound collections for CNS penetration. The ability to quantify permeability coefficients (Papp) and efflux ratios under physiological shear stress provides more accurate predictions than parallel artificial membrane permeability assays (PAMPA) or standard transwell models. Compounds with Papp > 5×10⁻⁶ cm/s and efflux ratio < 2 are considered CNS-penetrant [3].

Nanoparticle and Exosome Delivery

BBB-oC models are extensively used to evaluate nanoparticle-based drug delivery strategies. Functionalized nanoparticles targeting transferrin receptor, LRP1, or insulin receptor can be tested for transcytosis efficiency and toxicity. Polymeric, lipid, and extracellular vesicle formulations are screened for their ability to cross the BBB without compromising barrier integrity [2].

Neurotoxicity Assessment

Environmental toxins, heavy metals, and candidate drugs can be evaluated for BBB disruption and neuronal toxicity. Cadmium, lead, and methylmercury cause dose-dependent increases in BBB permeability through oxidative stress and tight junction disruption. BBB-on-chip platforms with integrated neurons enable differentiation of direct neurotoxicity from secondary toxicity caused by barrier compromise [10].

Disease Modeling

• Multiple Sclerosis (MS): Iron oxide nanoparticles and inflammatory cytokines (TNF-α, IL-1β, IFN-γ) induce MS-like tight junction disruption and increased permeability.
• Alzheimer's Disease: Amyloid-β oligomers disrupt BBB tight junctions and reduce P-glycoprotein expression, contributing to cerebral amyloid angiopathy.
• Ischemic Stroke: Oxygen-glucose deprivation (OGD) models recreate hypoxic-ischemic BBB breakdown, enabling evaluation of neuroprotective agents.
• Glioblastoma: Tumor-vascular interactions, BBB disruption in tumor regions, and drug delivery across the tumor-brain barrier can be modeled with patient-derived cells [5].

7. Technical Specifications and Operating Parameters

8. Conclusion

BBB-on-chip technology has overcome the limitations of conventional in vitro models by recreating the dynamic neurovascular microenvironment with physiological shear stress, multicellular interactions, and 3D architecture. These platforms achieve TEER values and permeability coefficients approaching in vivo human BBB properties, enabling predictive CNS drug screening, neurotoxicity assessment, and mechanistic disease modeling. GBiowit provides state-of-the-art BBB-on-chip platforms, neurovascular cell-compatible media, specialized matrices, and expert CNS drug screening services.

返回技术文章列表